Dissolution of tamoxifen in biorelevant media. A two phase release model

Farmacia

Volumn 60, Issue 3, 2012, Pages 315-324

  Mircioiu, Ion ^a   Anuta, Valentina ^b   Ibrahim, Nagwa ^b   Mircioiu, Constantin ^b  

^a UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Biorelevant dissolution media; Release kinetics modelling; Tamoxifen

Indexed keywords

ACETIC ACID; HYDROCHLORIC ACID; PANCREATIN; PEPSIN A; PHOSPHATIDYLCHOLINE; SANDOZ; SODIUM CHLORIDE; SODIUM HYDROXIDE; TAMOXIFEN CITRATE; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; WATER;

ARTICLE; BILE SECRETION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; FOOD INTAKE; IN VIVO STUDY; OSMOLALITY; PH; REGRESSION ANALYSIS; SURFACE TENSION; TABLET;

EID: 84863198887     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mircioiu C., Voicu V., Miron D., Mircioiu I: Non Standard Correlations: In vitro in vivo Correlations for Immediate Release Products: Comparison of Different Bioequivalence Experiments-Basic and Clinical Pharmacology and Toxicology 2005, 96, 259-261
2. Mircioiu C., Mircioiu I., Voicu V., Miron D: Dissolution-bioequivalence noncorrelations. Basic and Clinical Pharmacology and Toxicology 2005, 96, 262-264
3. Dressman, J. B.; Amidon, G. L.; Reppas, C.; Shah, V. P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15 (1), 11-22.
4. Vertzoni, M.; Dressman, J.; Butler, J.; Hempenstall, J. Reppas, C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 2005, 60 (3), 413-417.
5. Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 2008, 25 (7), 1663-1676.
6. Tormey DC, Gray R, and Falkson HC. Postchemotherapy adjuvant Tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst. 1996; 88: 1828-33.
7. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant Tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study. J Natl Cancer Inst. 1995; 87: 645-51.
8. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15 (5), 698-705.
9. Tetko IV, Tanchuk VY, Villa AE.-Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices J Chem Inf Comput Sci. 2001;41(5):1407-21.
10. Amidon GL, Lennernäs H, Shah VP, Crison JR: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12 (3): 413-20.
11. Nicolaides, E.; Galia, E.; Efthymiopoulos, C.; Dressman, J.B.; Reppas, C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 1999, 16 (12), 1876-1882.
12. Dressman, J. B.; Reppas, C. In vitro-in vivo correlations for lipophilic, poorly watersoluble drugs. Eur. J. Pharm. Sci. 2000, 11 (Suppl 2), 73-80.
13. Nicolaides, E.; Symillides, M.; Dressman, J. B.; Reppas, C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 2001, 18 (3), 380-388.
14. Nicolaides, E.; Symillides, M.; Dressman, J. B.; Reppas, C. United States Pharmacopeia 30-National Formulary 25, Rockville MD: United States Pharmacopeia Convention, Inc.; 2007.
15. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/4252fnl.pdf